Evidence-based Medicine
Experts question unusual authorization plan for Covid vaccine for kids under 5.
4 Feb, 2022 | 09:57h | UTCExperts question unusual authorization plan for Covid vaccine for kids under 5 – STAT
Related:
Pfizer asks FDA to allow COVID-19 vaccine for kids under 5 – Associated Press
Pfizer Asks FDA to Approve Its Vaccine for the Youngest Children – HealthDay
Research methods & reporting: Incorporating dose effects in network meta-analysis.
1 Feb, 2022 | 08:39h | UTCIncorporating dose effects in network meta-analysis – The BMJ
See also: thread from the author on Twitter summarizing the article
They built a smarter approach to Covid clinical trials. Now they want to do the same for other diseases.
28 Jan, 2022 | 08:31h | UTC
Opinion: Stamp out fake clinical data by working together.
27 Jan, 2022 | 09:31h | UTCStamp out fake clinical data by working together – Nature
Perspective: The value of patient-reported outcomes in early-phase clinical trials.
26 Jan, 2022 | 01:47h | UTCThe value of patient-reported outcomes in early-phase clinical trials – Nature Medicine (if the link is paywalled, try this one)
Commentary on Twitter
A @NatureMedicine Comment article argues that patient-reported outcomes, if used correctly, can provide preliminary evidence of efficacy and tolerability from a patient perspective, as well as supporting regulatory review. https://t.co/4ztwW76P2T pic.twitter.com/6sFRvswgJ2
— Nature Portfolio (@NaturePortfolio) January 24, 2022
A review of high impact journals found that misinterpretation of non-statistically significant results from randomized trials was common.
26 Jan, 2022 | 01:50h | UTC
Developing a how-to-guide for Health Technology Reassessment: “The HTR Playbook”.
25 Jan, 2022 | 09:26h | UTC
Massive open index of scholarly papers launches – “OpenAlex catalogues hundreds of millions of scientific documents and charts connections between them”.
25 Jan, 2022 | 09:04h | UTCMassive open index of scholarly papers launches – Nature
Perspective: Preventing digital overdiagnosis.
24 Jan, 2022 | 08:14h | UTCPreventing Digital Overdiagnosis – JAMA (free for a limited period)
Related: Overdiagnosis: it’s official – the term is now included in the medical subject headings (MeSH) vocabulary. (several articles on the subject)
A faster way to find good medical treatments is gaining ground – “A type of clinical trial that tests many therapies at once is being used for COVID and Alzheimer’s”.
24 Jan, 2022 | 07:50h | UTCA Faster Way to Find Good Medical Treatments Is Gaining Ground – Scientific American
Reporting of physicians’ or investigators’ choice of treatment in oncology randomized clinical trials.
24 Jan, 2022 | 07:49h | UTC
Commentary from the author on Twitter (thread – click for more)
Our new paper is out now in @JAMANetworkOpen !
When a randomized trial designs a « Physicians’ choice » or « Investigators’ choice » control arm, you might think :
« Great, the control arm is standard of care ! »
➡️ you may be surprised ???https://t.co/uho2pvXcG5— Timothée Olivier, MD (@Timothee_MD) January 21, 2022
The validity of progression-free survival 2 as a surrogate trial end point for overall survival.
21 Jan, 2022 | 09:31h | UTCThe validity of progression-free survival 2 as a surrogate trial end point for overall survival – Cancer (link to abstract – $ for full-text)
Rise of the preprint: how rapid data sharing during COVID-19 has changed science forever.
17 Jan, 2022 | 00:45h | UTC
Video: Is noninferior not inferior?
16 Jan, 2022 | 22:57h | UTCIs Noninferior Not Inferior? – NEJM Evidence
Commentary on Twitter
Stats, STAT! Watch this animated video that explores the basis for non-inferiority trials, the meaning of non-inferiority margins, and the interpretation of a non-inferiority trial’s results. #MedEd #ClinicalTrials https://t.co/wvDAHbQu8l pic.twitter.com/Z0LyJv1sN1
— NEJM Evidence (@NEJMEvidence) January 11, 2022
Analysis: Sarcopenia: early prevention or overdiagnosis?
16 Jan, 2022 | 22:48h | UTCSarcopenia: early prevention or overdiagnosis? – The BMJ
Related: Overdiagnosis: it’s official – the term is now included in the medical subject headings (MeSH) vocabulary. (several articles on the subject)
Commentary from the author on Twitter
We have a new diagnosis! 2 billion people may turn into patients with sarcopenia. Despite no evidence to justify why we should diagnose elderly people. My latest article in @bmj_latest with @drjohnbrodersen and JBülow. #overdiagnosis #sarcopenia #EBM https://t.co/mNFxmuz4U1
— Christoffer Bjerre Haase (@BjerreHaase) January 13, 2022
Coming to consensus: the Delphi technique.
16 Jan, 2022 | 22:54h | UTCComing to consensus: the Delphi technique – European Journal of Cardiovascular Nursing
Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations.
13 Jan, 2022 | 08:13h | UTC
Perspective: What Sci-Hub’s latest court battle means for research.
12 Jan, 2022 | 08:32h | UTCWhat Sci-Hub’s latest court battle means for research – Nature
Medical Decisions: Some are Easy and Some Not So Much.
11 Jan, 2022 | 02:31h | UTCMedical Decisions: Some are Easy and Some Not So Much – Stop and Think blog, by John Mandrola
Commentary on Twitter
Preventive therapy reduces the probability of a negative outcome. There are 2 big snags with preventive therapy:
1. All medical interventions come with the potential for harm.
2. Preventive therapies have modest effect sizes.
great read by @drjohnm https://t.co/Hk8VPnUv3m— Tjasa Zajc (@zajctjasa) January 9, 2022
5 things we learned about journal peer review in 2021.
8 Jan, 2022 | 22:51h | UTC5 Things We Learned About Journal Peer Review in 2021 – Absolutely Maybe Blog, by Hilda Bastian
Related:
A billion-dollar donation: estimating the cost of researchers’ time spent on peer review.
The $450 question: Should journals pay peer reviewers?
Opinion: Peer reviewers—time for mass rebellion?
5 things we learned about peer review in 2020
Editorial: Evaluation and Peer Review During a Pandemic
Review uncovers weak COVID clinical practice guidelines.
16 Dec, 2021 | 10:31h | UTCReview uncovers weak COVID clinical practice guidelines – CIDRAP
Commentary on Twitter
This systematic review found that few clinical practice guidelines for pharmacologic treatment of hospitalized patients with #COVID19 met the National Academy of Medicine standards for trustworthy guidelines. https://t.co/nOCDp4pJWx
— JAMA Network Open (@JAMANetworkOpen) December 10, 2021
Year In Review: Top Non-COVID Infectious Diseases Articles Of 2021.
17 Dec, 2021 | 08:36h | UTCYear In Review: Top Non-COVID Infectious Diseases Articles Of 2021 – IDStewardship
Commentary on Twitter
??NEW ??
My new post a great collaboration w the amazing @IDstewardship
Year In Review: Top✨ Non-COVID Infectious Diseases Articles Of 2021
18 high quality ? RCTs
6 RCTs @NEJM#Shorterisbetter #IDTwitter #MedEd #TwitteRx #ASPchat #SoMeDocs
Others?https://t.co/wJtdjYJ0Gf pic.twitter.com/ugILKX5RQO— Antibiotic Stewa®️x? Bassam Ghanem (@ABsteward) December 17, 2021
Opinion: Decision makers need constantly updated evidence synthesis.
16 Dec, 2021 | 08:39h | UTCDecision makers need constantly updated evidence synthesis – Nature
Perspective | ‘It’s misinformation at worst.’ Weak health studies can do more harm than good, scientists say.
7 Dec, 2021 | 10:17h | UTC
Discordant and inappropriate discordant recommendations in consensus and evidence based guidelines: empirical analysis.
5 Dec, 2021 | 23:14h | UTCEditorial: A moratorium on strong recommendations is needed – The BMJ
Commentary: Can we trust strong recommendations based on low quality evidence? – The BMJ
Commentary on Twitter
NEW research finds that consensus based guidelines produce more recommendations violating the evidence based medicine principles than evidence based guidelines https://t.co/8eCGZfiNZ3
— The BMJ (@bmj_latest) November 28, 2021